MPN10 score and survival of molecularly annotated myeloproliferative neoplasm patients

作者：ElNahass Yasser H; Mahmoud Hossam K; Mattar Mervat M; Fahmy Omar A; Samra Mohamed A; Abdelfattah Raafat M; ElRefaey Fatma A; Fahmy Hala M; Fathy Gamal M; Abdulgawad Ahmed; AbdelKader Mohamed; Elleithy Hend N; Gamil Mona; Talaat Mohamed; Nader Heba A; ElMetnawy Wafaa H

来源：Leukemia and Lymphoma, 2018, 59(4): 844-854.

DOI：10.1080/10428194.2017.1365852

• Myeloproliferative neoplasms
• JAK2
• calreticulin
• triple negative
• MPN10 score
• survival

JAK2, CALR, MPL and triple-negative mutational status has a direct impact on symptom severity and disease burden assessed by MPN10 score in myeloproliferative neoplasms (MPNs). Among 93 patients; median MPN10 score was 48 (5-76) in JAK2 mutants versus 25 (4-80) in JAK2 negative (p<.001); 22.5 (4-65) in CALR mutants versus 35 (5-80) in CALR negative (p<.050) and 21 (10-48) in triple negative versus 40 (4-80) in JAK2/CALR/MPL mutants (p<.001). At three years, progression free and overall survival of JAK2-positive versus JAK2-negative patients were 62% versus 100% (p<.001); 85% versus 100% (p=.011) and were 100% versus 78% (p=.067); 100% versus 92% (p=.197) in CALR-positive versus CALR-negative patients and 100% versus 75% (p=.004); 100% versus 90% (p=.015) in triple negative versus mutant patients, respectively. MPN10 score in association with driver gene mutations can be used as a predictor of survival in MPN patients.

• 出版日期2018